Stock Taper 
| DATE | TYPE | RATIO |
|---|---|---|
| 2024-02-12 | Reverse | 1:12 |
| 2014-07-14 | Reverse | 1:5 |
Assembly Biosciences, a clinical-stage biotech based in South San Francisco, develops HBV therapies like Vebicorvir (Phase 2), ABI-H3733 (Phase 1a), and preclinical candidates, collaborating with partners including BeiGene and Arbutus.
ABI-4334 is an oral, investigational capsid assembly modulator targeting chronic hepatitis B, demonstrating potent antiviral activity in Phase 1b, with the goal of achieving a functional cure for HBV.
In a significant strategic move, Gilead Sciences exercised its option to license Assembly Biosciences' helicase-primase inhibitor programs for recurrent genital herpes. This decision followed the release of positive interim Phase 1b clinical data for the candidates ABI-1179 and ABI-5366, representing a major validation of Assembly Bio's scientific platform and a crucial step towards potential commercialization.
In a significant strategic move to strengthen its financial position, Assembly Biosciences announced the pricing of a $175 million equity financing. This capital infusion is intended to fund the company's operations into mid-2026, enabling the advancement of its clinical trials and expansion of research efforts in serious viral diseases.
Assembly Biosciences (NASDAQ: ASMB - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Profitability This table compares Assembly Biosciences and RYTHM's
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
Overall rating: C
| PEER | PRICE | |
|---|---|---|
 VIR | $11.06 | COMPARE |
 ABUS | $4.17 | COMPARE |
 AVIR | $5.18 | COMPARE |
 ZURA | $4.01 | COMPARE |
 ARCT | $13.24 | COMPARE |
 ENTA | $12.23 | COMPARE |
 SGMT | $8.77 | COMPARE |
 INDP | $2.35 | COMPARE |
